Wednesday November 6, 2024

12:00-13:00

Registration

13:00-13:15

Welcome

Opening session

13:20-13:40

Cardio-oncology: a call to action for the scientific community

Thomas Lüscher

13:40-13:55

Discussion. 

14:00 - 14:55 TRACK 1 Overhauling the Red Devil

14:00-14.10

Case presentation

Martina Iengo

14:10-14:20

New avenues in anthracycline cardiotoxicity prevention

Tienush Rassaf

14:20-14:30

Cardiac and skeletal muscle energetic pathways

Dana Dawson

14:30-14:40

Pathophysiological mechanisms underlying late-onset doxorubicin-induced cardiotoxicity

Peter Van der Meer

14:40-14:55

Discussion. Take home messages

15:00 - 15:55 TRACK 2 New perspectives in immunotherapy-related cardiovascular toxicities

15:00-15:10

Case presentation

Laura Gutiérrez

15:10-15:20

Immunotherapy and the troponin dilemma

Lorenz Lehmann

15:20-15:30

Immune checkpoints and heart failure: the hen or the egg

Wouters Meijers

15:30-15:40

Innate immune receptors, key actors in cardiovascular diseases

María Fernández Velasco

15:40-15:55

Discussion. Take home messages

16:00 - 16:30

Coffee break

16:30 - 17:25 TRACK 3 New approaches to the prevention of cardiotoxicity.

16:30-16:40

Case presentation

Irene Marco Clement

16:40-16:50

Polygenic Risk Scores for Cardiotoxicity: fact or fiction?

Anna González Neira

16:50-17:00

Single-cell resolution of cardiotoxicity in (pre) clinical models

Alessandra Ghigo

17:00-17:10

Quality standards for pre-clinical research in cardio-oncology

Pietro Ameri

17:10-17:25

Discussion. Take home messages

17:30 - 18:25 TRACK 4 Cardio-oncology from bench to bedside

17:30-17:45

Resilience trial update

Borja Ibáñez

17:45-18:00

SIR-CVT update

Pilar Martín

18:00-18:15

Trials of tomorrow: shaping the future of hematology clinical research

Fátima Mirás

18:15-18:25

Discussion

18:30

Closing remarks